Pethema Multiple Myeloma 2000

Clinical Trial ID NCT00560053

PubWeight™ 11.77^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00560053

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.	Blood	2008	2.74
2	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.	Blood	2008	2.34
3	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.	Leukemia	2013	1.20
4	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.	Blood	2009	1.10
5	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.	Haematologica	2009	1.08
6	Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.	Biol Blood Marrow Transplant	2012	0.92
7	Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.	Br J Haematol	2013	0.91
8	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.	Haematologica	2010	0.90
9	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.	Haematologica	2011	0.84